MDMA-assisted Therapy

Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
Could MDMA Revolutionize PTSD Treatment? In Historic Move, FDA Considers New Drug Application
Atai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatment
Could MDMA Revolutionize PTSD Treatment? In Historic Move, FDA Considers New Drug Application
Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News

MDMA-assisted Therapy Recent News

MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice (GMP)-compliant MDMA to conduct a therapist-experiential training program. 
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr.
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?
Revolutionizing Psychedelics: 2 Industry Leaders Collaborate To Offer Clinical-Grade MDMA Capsules
MDXX-class molecules producer PharmAla Biotech Holdings Inc.
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech Holdings Inc.
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn Life Sciences (OTCMKTS: AWKNF).
Australia's Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as post-traumatic stress disorder and psilocybin for treatment-resistant depression.
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
MDMA Therapy For Chronic PTSD: Neuroimaging With Veterans & First Responders Provides Further Evidence
The legendary non-profit’s private arm, MAPS Public Benefit Corporation (MAPS PBC), announced that Frontiers in Psychiatry has published its first functional neuroimaging study evaluating how MDMA-assisted therapy work
Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More
Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's Senate Health Committee.
MDMA For PTSD Shows Positive Results In Important Clinical Trial: Are Psychedelic Treatments Around The Corner?
MAPS Public Benefit Corporation (MAPS PBC), the non-profit’s private biopharma leg developing psychedelic medicines, announced positive results from MAPP2, the company’s second Phase 3 study assessing MDMA-assisted therap
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
MAPS Completes Second Phase 3 Trial Of MDMA-Assisted Therapy For PTSD, Topline Data & New Drug Application Next
MAPS Public Benefit Corporation (PBC) announced the final participant’s last Evaluation and Exit Planning therapeutic session was completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD.)
Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage
Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01
Awakn Shares Its Q2 2022 Results, Showing Consistent Growth On Its Second Full Financial Year
Biotech firm leading the Alcohol Use Disorder (AUD) treatment Awakn Life Sciences Corp. (OTCQB: AWKNF) has announced its financial outcomes and business highlights for the three months ended July 31, 2022. During the period, numbers reflected:
Canadian Psychedelics Company Reduces Manufacturing Time Of MDMA By Two Thirds
Nirvana Life Sciences Inc. (CSE: NIRV) announced that it has engineered a method that reduces the manufacturing time of MDMA by two thirds.
Canada: MDMA-Assisted Therapy Trials Reviewed By Health Canada, Here's What's Happening
Health Canada has just completed a review of all active MDMA-assisted psychotherapy trials, in response to alleged patient safety issues and research flaws. The issues had resulted in one of the two existing studies being suspended while the other allowed to proceed with some "corrective and preventive" changes.
Missouri Patients With Life-Threatening Illnesses Can Seek Psychedelic Treatments Under 'Right To Try' Law
Rep.
Australian Psychiatrist Sues State Of Victoria For Denying MDMA Treatment For Ailing Patient
The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness.